secwatch.observer — SEC 8-K summary
======================================

Issuer:     Artiva Biotherapeutics, Inc. (ARTV)
CIK:        0001817241
Form:       8-K
Filed at:   2026-09-11T20:21:51+00:00
Accession:  0001193125-26-389308
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artiva shareholders approve 5.1M share increase to 2024 equity plan at annual meeting
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2024 Equity Incentive Plan adding 5,097,095 shares to Share Reserve.
- Vote on plan amendment: 32,527,133 for, 6,816,989 against, 22,759 abstentions, 4,640,922 broker non-votes.
- Class II directors Brian Daniels, M.D. and Laura Stoppel, Ph.D. elected for three-year terms through 2029.
- KPMG LLP ratified as independent auditor for FY2026: 44,000,762 for, 4,325 against, 2,716 abstentions.
- Amended plan also counts pre-funded warrant shares in annual automatic reserve increase (starting Jan 1, 2027).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526389308/0001193125-26-389308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817241/000119312526389308/artv-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-389308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer